Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
drugs
8
×
fda
8
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
8
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
cancer
eli lilly
astrazeneca
celgene
gene therapy
investing
merck
multiple myeloma
sarepta therapeutics
startups
What
bio
drug
fda
roundup
new
week
approved
big
companies
disease
drugs
known
make
medical
meeting
ahead
alzheimer’s
american
annual
approval
arguments
asco
ash
assessed
attention
biopharma
biotech
biotechs
blood
branded
cancer
choices
chose
class
close
commercialized
commissioner
communities
company
competitors
Language
Current search:
drugs
×
fda
×
" seattle blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way